PARP1 and ST Elevation Myocardial Infarction: In a randomized, placebo-controlled, single-blind clinical trial involving 40 patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention, bolus intravenous administration of the PARP-1 inhibitor, INO-1001, reduced in vitro PARP-1 activity in the plasma of these patients, with a corresponding decrease in the levels of plasma C-reactive protein and IL-6 [103].